Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment
Sponsor: Pfizer
Summary
The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function. This study is seeking participants who: * Have moderate or severe renal impairment or * Healthy people with normal kidney function All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function. Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.
Official title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-11-17
Completion Date
2028-05-27
Last Updated
2026-11-12
Healthy Volunteers
Yes
Conditions
Interventions
Prifetrastat
Prifetrastat administered by mouth as a single dose.
Locations (3)
Floridian Clinical Research
Miami Lakes, Florida, United States
Genesis Clinical Research, LLC
Tampa, Florida, United States
Nucleus Network Minneapolis
Saint Paul, Minnesota, United States